Abstracts tagged "Comorbidity"

Abstract Number: 2021 • ACR Convergence 2024
The Dual Benefits of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Nephrolithiasis and Gout Flares Among Gout Patients with Type 2 Diabetes: New User, Active Comparator Target Trial Emulation Studies
Natalie McCormick¹, Chio Yokose², Leo Lu³, Deborah Wexler¹, J. Antonio Avina-Zubieta⁴, Mary A. De Vera⁵, saiajay chigurupati¹, Kiara Tan¹, Chixiang Chen⁶, Rozalina McCoy⁶, Gary Curhan⁷ and Hyon K. Choi⁸, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ⁵University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, ⁶University of Maryland, School of Medicine, Baltimore, MD, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Massachusetts General Hospital, Lexington, MA
Background/Purpose: Nephrolithiasis and gout are both common, extremely painful conditions which frequently coexist, along with type 2 diabetes (T2D). Sodium-glucose cotransporter-2 inhibitors (SGLT2i), first approved…
Abstract Number: 1097 • ACR Convergence 2024
CERT Score as a Potential Tool to Predict Cardiovascular Risk in Gout and Hyperuricemia
Blanka Stiburkova¹, Aleš Kvasnička², Barbora Pisklakova², Jakub Rozhon², Karel Pavelka³ and David Friedecky², ¹Institute of Rheumatology, Prague, Czech Republic and Department of Paediatrics and Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic, Prague, Czech Republic, ²Laboratory for Inherited Metabolic Disorders, Department of Clinical Biochemistry, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic, Olomouc, Czech Republic, ³Institute of Rheumatology and Charles University, Praha, Czech Republic
Background/Purpose: Asymptomatic hyperuricemia and gout are two clinical conditions associated with a high risk of cardiovascular events and mortality. Recent data suggest that the number…
Abstract Number: 2024 • ACR Convergence 2024
Serum Urate Change Among Patients with Gout Treated with Anti-Hypertensive Medications: A Comparative Effectiveness Analysis
Chio Yokose¹, saiajay chigurupati², Bohang Jiang², Kiara Tan², Natalie McCormick² and Hyon K. Choi³, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: Hypertension is the most common comorbidity among patients with gout, with a prevalence of nearly 75% among patients with gout. Losartan and calcium channel…
Abstract Number: 1101 • ACR Convergence 2024
The Contemporary Prevalence of Comorbid Gout and Chronic Kidney Disease, Two Common Conditions with High Morbidity, in the US General Population
Chio Yokose¹, Leo Lu², Sharan Rai³, Natalie McCormick³ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Waltham, MA, ²Arthritis Research Canada, Vancouver, BC, Canada, ³Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Gout and chronic kidney disease (CKD) are both common conditions which are associated with high morbidity and mortality and often coexist. We sought to…
Abstract Number: 2110 • ACR Convergence 2024
Association Between Symptomatic Knee Osteoarthritis and Blood Glucose Control in Persons with Type 2 Diabetes
Lauren King¹, Alanna Weisman¹, Baiju Shah¹, Robert Goldberg¹, Amish Parikh², Ian Stanaitis³, Rosane Nisenbaum⁴, Esther Waugh¹, Lorraine Lipscombe¹ and Gillian Hawker¹, ¹University of Toronto, Toronto, ON, Canada, ²Trillium Health Partners, Toronto, ON, Canada, ³Women's College Hospital, Toronto, ON, Canada, ⁴Li Ka Shing Knowledge Institute, St Michael’s Hospital, Toronto, ON, Canada
Background/Purpose: There is a high prevalence of knee osteoarthritis (OA) in people with type 2 diabetes (T2D), and knee OA increases risk for diabetes complications…
Abstract Number: 1116 • ACR Convergence 2024
Understanding the Prevalence, In-Hospital Mortality and Readmission Rates Amongst Pulmonary vs Cardiac Sarcoidosis Patients: Insights from a Nationwide Registry
Shivang Chaudhary¹, Kaushik Gokul¹, Kishan Patel², Simran Bhimani³, Yash Deshpande³, Adam Kilian¹, Ravi Nayak¹, Deana Mikhalkova¹ and Chaitanya Rojulpote¹, ¹Saint Louis University, St. Louis, MO, ²Riverside Community Hospital, Riverside, CA, ³The Wright Center for graduate medical education, Scranton, PA
Background/Purpose: Sarcoidosis is a complex, multisystemic disorder predominantly affecting the pulmonary system but can also involve extra-pulmonary organs such as the heart. Mortality in sarcoidosis…
Abstract Number: 2171 • ACR Convergence 2024
A Qualitative Exploration of Oral Healthcare Needs Amongst Canadian Patients with Rheumatic Diseases and Their Providers
Chrysi Stavropoulou¹, Corrie Billedeau², Jennifer Protudjer¹ and Carol Hitchon¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²NA, Winnipeg, MB, Canada
Background/Purpose: Patients with autoimmune rheumatic diseases (RDs) have a high prevalence of oral manifestations and/or oral side effects from immunomodulatory medications. These factors combined with…
Abstract Number: 1216 • ACR Convergence 2024
Subcutaneous Methylnaltrexone Treatment of Opioid-Induced Constipation in Adults with Rheumatic Conditions
Larry Moreland¹, Rowe Brookfield² and Adam Laitman², ¹University of Colorado, Denver, CO, ²Salix Pharmaceuticals, Bridgewater, NJ
Background/Purpose: In patients taking opioid analgesics, opioid-induced constipation (OIC) is estimated to affect between 41% to 80% of patients and is caused by peripheral mu-opioid…
Abstract Number: 2230 • ACR Convergence 2024
Relationship Between the Complement System and Serum Lipid Profile in Patients with Rheumatoid Arthritis
Maria Garcia-Gonzalez¹, Fuensanta Gomez-Bernal², Juan Carlos Quevedo-Abeledo³, Miguel Angel Gonzalez-Gay⁴ and ivan Ferraz-Amaro⁵, ¹Hospital Universitario de Canarias, SC Tenerife, Canarias, Spain, ²Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ³Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, ⁴University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁵Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain
Background/Purpose: The complement system has been linked to the etiopathogenesis of rheumatoid arthritis (RA). Patients with RA exhibit a dysregulated profile of lipid molecules, which…
Abstract Number: 1239 • ACR Convergence 2024
Innovative Patient Empowerment: Evaluating the Effect of a Physician-created Educational Video and To-do Lists on Promoting Preventive Health Measures in Rheumatic Disease Patients
Vanessa Bartsch¹, Basel Habboub², Kathrin Standfest¹, Johannes Knitza³, Georg Schett⁴ and Axel Hueber², ¹Division Rheumatology, Klinikum Nuernberg, Nuernberg, Germany, ²Klinikum Nuernberg, Nuernberg, Germany, ³Institute for Digital Medicine, Philipps-University Marburg and University Hospital of Giessen and Marburg, Marburg, Germany, ⁴Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Patients with inflammatory rheumatic diseases (IRDs) are at higher risk for malignancies and infections. Effective management strategies for these comorbidities are urgently needed. We…
Abstract Number: 2321 • ACR Convergence 2024
Prevalence and Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease
Nahia Plaza-Aulestia¹, Oihane Ibarguengoitia-Barrena², Blanca Sampedro-Andrada³, Cristina San Juan-Lopez³, Victoria Morillo-Montañes⁴, Irati Urionaguena⁵, Itziar Calvo⁶, David Montero Seisdedos⁷, Lucia Vega-Alvarez², Jose Francisco Garcia Llorente² and Nuria Vegas Revenga⁸, ¹Rheumatology Division, Galdakao-Usansolo University Hospital, Galdakao, Spain, ²Rheumatology Division, Galdakao-Usansolo University Hospital, Bilbao, Spain, ³Digestive Division, Galdakao-Usansolo University Hospital, Galdakao, Spain, ⁴Dermatology Division, Galdakao-Usansolo University Hospital, Galdakao, ⁵Rheumatology Division, Galdakao-Usansolo University Hospital, GERNIKA-LUMO, Spain, ⁶Hospital Universitario de Basurto, Bilbao, Spain, ⁷Galdakao-Usansolo University Hospital, Bilbao, Spain, ⁸Hospital Galdakao- Usansolo, Galdakao, Spain
Background/Purpose: Patients with psoriatic disease (PsD) [psoriasis (PsO) and psoriatic arthritis (PsA)] are at greater risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD) compared…
Abstract Number: 0223 • ACR Convergence 2024
A Comparative Study of Difficult-to-Treat vs Non-Difficult-to-Treat Psoriatic Arthritis for Disease Burden and Comorbidities: An Ultrasound Study
Ricardo Sabido-Sauri¹, Seyyid Bilal Acikgoz², Ozun Bayindir Tsechelidis³, Ummugulsum Gazel¹, Sylvia Sangwa⁴, Elliot Hepworth¹ and Sibel Aydin⁵, ¹University of Ottawa, Ottawa, ON, Canada, ²University of Ottawa, Rheumatology, Ottawa, ON, Canada, ³Ottawa University, Ottawa, ON, Canada, ⁴The Ottawa Hospital Research Institute, Ottawa, Canada, ⁵University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: In the era of several advanced therapies and an increased number of patients with psoriatic arthritis (PsA) who have been failed by multiple treatment…
Abstract Number: 1245 • ACR Convergence 2024
Inpatient Discontinuation of Allopurinol – A Quality Improvement (QI) Initiative
Stephanie Tancer¹, Basmah Al Dulaijan² and Puja Khanna³, ¹University of Michigan Department of Internal Medicine, Division of Rheumatology, Ann Arbor, MI, ²Michigan Medicine, Ann Arbor, MI, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Gout is a chronic inflammatory arthritis induced by hyperuricemia and manifested by recurrent acute flares of debilitating joint pain when left untreated. Allopurinol is…
Abstract Number: 2337 • ACR Convergence 2024
Patient Characteristics and Outcomes of Emergency Visits in Psoriatic Arthritis: Results from the U.S. Nationwide Emergency Department Sample (NEDS)
Dominique Feterman Jimenez¹, Rachael Stovall¹, Jose Andres Porres Arnaez², Vishwesh Bharadiya³, Jean Liew⁴, Alison Bays¹, Thomason Jenna⁵, Londyn Robinson⁶, Rashmi Dhital⁷ and Namrata Singh⁸, ¹University of Washington, Seattle, WA, ²Universidad Francisco Marroquin, Guatemala, ³AIIMS, New Delhi, India, ⁴Boston University, Boston, MA, ⁵University of Washington, Division of Rheumatology, Seattle, WA, ⁶University of Washington, Durham, NC, ⁷UC San Diego, Brentwood, TN, ⁸University of Washington, Bellevue, WA
Background/Purpose: Compared with the general population, patients with psoriatic arthritis (PsA) have a higher risk of comorbidities and all-cause mortality. They are also at increased…
Abstract Number: 0292 • ACR Convergence 2024
Liver Disease Complicating Familial Mediterranean Fever: A Study on 57 Patients from the French Adult JIR Cohort
Marion Delplanque¹, xavier amiot², Dominique Wendum³, françois Rodrigues², Rim bourguiba¹, Benoit Terris⁴, Christophe Duvoux², Pierre Bedossa⁵, Didier lebrec⁵, Philippe Sogni², Lucia parlati², Frederic Charlotte², Vlad Ratziu², stephane mouly⁶, jeremy augustin², julien Calderaro², giovana scoazec², JM Vignaud⁷, JA Seyrig⁸, Gilles Grateau¹, Lea Savey⁹ and Sophie Georgin-lavialle¹⁰, ¹Internal Medicine Department, Tenon Hospital, AP-HP, Paris, France, Paris, France, ²APHP, Paris, ³APHP, Paris, France, ⁴Department of pathology, Hôpital Cochin, GHU Paris Centre, AP-HP, Université Paris Cité,, Paris, France, ⁵APHP, clichy, ⁶Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, Ile-de-France, France, ⁷CHRU nancy, Nancy, ⁸CH centre bretagne, pontivy, ⁹Internal Medicine Department, Tenon Hospital, AP-HP, Paris, France, france, France, ¹⁰Sorbonne Université, Department of internal medicine, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
Background/Purpose: Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease, associated with MEFV gene mutations. FMF patients can experience liver involvement, potentially leading…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].